- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02318186
Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (PKRemodulin)
Multi-center, Open-label Pharmacokinetic Study of Subcutaneously and Intravenously Administered Treprostinil in Children With Pulmonary Arterial Hypertension (PAH)
Abstract
This is a multi-center, open-label pharmacokinetic (PK) study examining the relationship between the steady-state plasma concentration and dose of treprostinil delivered intravenously or subcutaneously in children with pulmonary arterial hypertension (PAH). Subjects will be divided into 5 cohorts by age. A blood sample will be obtained from each subject at steady state. Additional blood samples will be obtained from a small subset of subjects with a 15% increase or with at least a 15ng/kg/min increase in dose from steady state. Samples will be sent to a pharmacokinetic laboratory for analysis. Linear regression analysis will be used to determine the relationship between the steady state plasma concentration and drug dose. A power model will be used to assess dose proportionality.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Background Information and Rationale
Treprostinil has not been adequately studied to determine its safety and efficacy in children ≤ 16 years old. However, the drug's use and tolerance in children with PAH has been demonstrated in studies with small sample sizes.
Although the pharmacokinetic relationship of treprostinil has been established in adult patients with PAH, the relationship between the steady-state plasma concentration and dose for children requires further investigation because of physiologic differences, such as the maturity of enzyme systems and drug clearance mechanisms, between children and adults. The subjects in this study will be divided into cohorts by age to address the physiologic changes that occur throughout childhood.
Currently, no data exists demonstrating the relationship between the steady-state plasma concentration and dose for children treated with intravenously or subcutaneously delivered treprostinil. Understanding the pharmacokinetics of treprostinil among different age cohorts in children will provide the data to make an informed recommendation for dosing based on age (and possibly weight).
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Lucille Packard Children's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients must be on continuous intravenous or subcutaneous treprostinil for the treatment of pulmonary arterial hypertension, defined as mean pulmonary artery pressure >25mmHg at rest with a PVRi > 3 Wood units.
- Patients must be between the ages of 0 to 16 years at the time of study enrollment.
- Written informed consent and assent, when applicable, must be completed.
Exclusion Criteria:
- Patients with severe liver or renal diseases.
- Female patients who may be pregnant or breastfeeding
- Written informed consent and assent not completed due to patient and/or parent or legal guardian unwilling to participate.
- Patients on concomitant use of a CYP2C inhibitor or inducer.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
0 months - 1 year
|
11-16 years
|
7-11 years
|
4-6 years
|
1-3 years
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
To determine the relationship between steady-state plasma concentration and dose of treprostinil within each age cohort and among age cohorts.
Periodo de tiempo: at least 48 hours after most-recent titration
|
A blood sample will be obtained from each subject at steady state.
Additional blood samples will be obtained from a small subset of subjects with a 15% increase or with at least a 15ng/kg/min increase in dose from steady state.
|
at least 48 hours after most-recent titration
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
To correlate PK level of treprostinil with the presence or absence of side effects
Periodo de tiempo: At time of blood draw
|
A survey of side effects (GI, neurological, cardiac, respiratory, skin) will be administered at time of blood draw.
|
At time of blood draw
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr. 2011 Apr;158(4):584-8. doi: 10.1016/j.jpeds.2010.09.025. Epub 2010 Oct 30.
- Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007 Mar 1;99(5):696-8. doi: 10.1016/j.amjcard.2006.09.119. Epub 2007 Jan 10.
- McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, Zwicke DL, Oudiz RJ, Staszewski JP, Arneson CP, Wade M, Zaccardelli D, McLaughlin V. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol. 2008 Jan;48(1):19-25. doi: 10.1177/0091270007309708.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UT PK Treprostinil
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hipertensión arterial pulmonar
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeTerminadoPresión arterial | Anestesia | Línea ArterialEstados Unidos
-
Auburn UniversityActivo, no reclutandoDormir | Presión arterial | Disfunción endotélica | Racismo | Rigidez ArterialEstados Unidos
-
AHEPA University HospitalTerminadoRigidez arterial | Monitoreo ambulatorio de la presión arterialGrecia
-
Unity Health TorontoTerminadoRigidez arterial, presión arterialCanadá
-
CID S.p.A.Meditrial Europe Ltd.Aún no reclutandoEnfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaItalia
-
Marissa JarosinskiReclutamientoEnfermedad arterial periférica oclusiva | Enfermedad vascular periférica | Enfermedad Arterial Periférica | Clopidogrel, metabolismo deficiente de | Enfermedad ArterialEstados Unidos
-
Istituto Auxologico ItalianoReclutamientoHipertensión arterial | Monitoreo ambulatorio de la presión arterial | Determinación de la presión arterial | Monitoreo de la presión arterial en el hogarItalia
-
ROX Medical, Inc.TerminadoHipertensión | Presión Arterial, Alta | Presión Arterial, Resistente | Presión Arterial, No ControladaReino Unido, Países Bajos, Bélgica
-
University of JyvaskylaBusiness Finland; Finnish Foundation for Cardiovascular Research; Harvia Finland...TerminadoPresión arterial | Factor de riesgo cardiovascular | Rigidez arterialFinlandia
-
University of NebraskaAún no reclutandoEnfermedad arterial periférica | Enfermedades vasculares periféricas | Enfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaEstados Unidos